AlzeCure Secures EU Grant Funding for Phase 2 Clinical Trial of NeuroRestore ACD856 in Alzheimer's Disease

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Dec 03 2025

0mins

Source: Yahoo Finance

Grant Received: AlzeCure Pharma has secured a EUR 2.5 million grant from the European Innovation Council to support a Phase IIa clinical study of its drug candidate NeuroRestore ACD856 for Alzheimer's disease treatment.
Drug Mechanism: ACD856 is designed to enhance brain signaling pathways related to cognition and memory, showing promise in improving learning and memory functions while also exhibiting neuroprotective and anti-inflammatory properties.
Significance of Alzheimer's Disease: Alzheimer's disease affects approximately 55 million people globally, with numbers expected to triple in the next 30 years, highlighting the urgent need for effective treatments.
Company Overview: AlzeCure Pharma is a Swedish biotech firm focused on developing innovative therapies for central nervous system diseases, with multiple drug candidates in various stages of research and development.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.